ClinicalTrials.gg
RecruitingNCT04184973Updated Jul 6, 2026

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

An interventional study of CG-100 intraluminal bypass device and Stoma in Rectal Cancer, Rectal Tumor and Rectal/Anal, sponsored by Colospan Ltd.. Recruiting at 10 sites in 5 countries. Open to participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Colospan Ltd. · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
22 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 781 studies in Rectal Neoplasms with a site in United States — 80 open to participants now, 141 under way, 9 of them phase 3. Rectal Neoplasms · United States.

Planned enrollment
93rd of 620
250 · median 39
Started
2020
with 30 others
No phase
149 of 781
24 open now
Primary completion
2026-12
later than 41 of 140 live
Registered
631st of 781
by date

Among the 781 studies in Rectal Neoplasms with a site in United States, this one is the 93rd largest by planned enrollment of the 620 interventional ones that give a count, is one of 31 that started in 2020, is one of 149 with no phase, reaches primary completion later than 41 of the 140 other live ones, and was the 631st registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

80 of the 781 studies in Rectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

75 more — sign in →

All 80 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 22 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 781 studies in Rectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.

Read the detailed description

A primary diverting stoma is widely used by surgeons in order to bypass the low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Today a stoma is created for all high-risk patients even though the expected anastomotic leak rate is less than 20%. This means that 80% of patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit.

CG-100, a removable, temporary intraluminal bypass device, developed by Colospan, is designed to address this need by safely postponing the creation of a protective stoma until 10 days after surgery only for patients who need it (i.e. have a defect in the anastomosis); thereby allowing patients with an intact anastomosis a quicker and safer return to normal activity.

03

Conditions studied

  • Rectal Cancer
  • Rectal Tumor
  • Rectal/Anal

Browse trials for

Keywords

  • anastomosis
  • leak
  • mesorectal
  • ileostomy
  • colostomy
04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is willing to comply with protocol-specified follow-up evaluations
  2. Patient 22-65 years of age at screening, or patient 66-70 years of age at screening with up to one cardiovascular, metabolic or pulmonary comorbidity for which medication is prescribed.
  3. Patient is diagnosed with colorectal cancer
  4. Patient is scheduled for elective either open, laparoscopic or robotic with mesorectal excision (either abdominal or transanal approach) which will require the creation of an anastomosis, maximally 10 cm from the anal verge
  5. Patients who are scheduled to receive a protective stoma under routine clinical practice during their primary planned operation.
  6. Patient is scheduled to undergo mechanical bowel preparation
  7. The patient has been informed of the nature of the study, agrees to its provisions and has provided written , approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB).

Exclusion criteria

Exclusion Criteria:

  1. Patient has local or systemic infection at the time of intervention (e.g., peritonitis)
  2. Major surgical or interventional procedures within 45 days prior to this study or planned surgical or interventional procedures within 6 months of entry into this study (not including, placement of port for chemotherapy or ureter stent insertion).
  3. Patients with > 3
  4. Albumin \< 30 g/liter
  5. Patient has a diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, ischemic bowel, carcinomatosis or extensively spread inflammatory bowel disease
  6. Patients has a diagnosis of coagulopathy, thrombocytopenia, immune suppression
  7. ≥ 40
  8. Patient is going through another surgical procedure (other than ileostomy, adhesiolysis) during the surgery.
  9. The patient is currently participating in another drug or device study unless pre-approved by the sponsor.
  10. Patient has been taking regular systemic/ medication in the last 6 months.
  11. Patients is taking antimetabolites or antiplatelet agents.
  12. Patient has preexisting sphincter problems
  13. Patient has evidence of extensive local disease in the pelvis or has undergone a prior pelvic anastomosis.
  14. Patients with massive diverticulosis at the sigmoid/descending colon (viewed on preoperative CT)
  15. Any condition or abnormality which in the opinion of the investigator may jeopardize the patient's safe participation or the quality of the data
  16. Pregnant or nursing female patients. Female patients of must have a negative pregnancy test done within 7 days prior to surgical procedure per site standard test.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    CG-100

    Patients receive CG-100 during rectal cancer surgery

    Device: CG-100 intraluminal bypass device

  • Active comparator
    SOC

    Patients receive a protective stoma during rectal cancer surgery

    Procedure: Stoma

Interventions

  • DeviceCG-100 intraluminal bypass device

    a removable, temporary intraluminal bypass device, developed by Colospan, is designed to safely postpone the creation of a protective stoma until 10 days after surgery only for patients who need it (i.e. have a defect in the anastomosis)

  • ProcedureStoma

    Primary protective ileostomy

06

What researchers measure

Primary outcomes

  1. Change in Stoma creation rate

    Time frame: 39 Weeks

  2. Incidence of complications

    Time frame: 39 Weeks

07

Study locations

7 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2026, 78 months after the start.

Of 336 interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2019
First posted
Dec 4, 2019
StartActual
Jun 23, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04184973
Lead sponsor
Colospan Ltd.
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Jun 23, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Boaz Assaf
Contact
boaz@colospan.com
+972-9-7672518
Shelly Sharon, MSc
Contact
Shelly@colospan.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion